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Impact of endograft design and product line on
the device cost of endovascular aneurysm repair
Robert J. Feezor, MD, Thomas S. Huber, MD, PhD, Scott A. Berceli, MD, PhD, Peter R. Nelson, MD,
James M. Seeger, MD, and W. Anthony Lee, MD, Gainesville, Fla
Objective: Device cost is a substantial component of the overall cost of endovascular abdominal aneurysm repair (EVAR),
and the four commercially available devices differ significantly in the cost of their basic configuration. This study
examined the impact of three different endografts and their product lines on the overall cost of repair.
Methods: Implant records of 467 EVAR procedures performed during 2000 through 2006 were reviewed. The three
devices used were the AneuRx in 178 (38.1%; Medtronic, Santa Rosa, Ca), the Excluder in 123 (26.3%; W. L. Gore &
Associates, Flagstaff, Ariz), and the Zenith in 166 (35.5%; the Cook Zenith (Bloomington, Ind). The Powerlink device
(Endologix, Irvine, Calif) was not studied. The specific device implanted was determined by its commercial availability at
the time of repair, patient anatomy, and surgeon preference. Retail list prices were used for all calculations, and only
devices used during the original repair were used for analysis.
Results: The device cost of the most basic configuration for repair (ie, 2 pieces for AneuRx and Excluder, 3 pieces for
Zenith) differed by $3022 between the most expensive (Zenith) to the least expensive (AneuRx). However, the AneuRx
system required the most number of extensions (1.90  1.25 per case; range, 0-7), whereas the Zenith required the fewest
(0.21  0.51 per case; range, 0-3). When the costs of the extensions were added, the overall mean device costs per case
were similar.
Conclusion: The initial cost advantage of the AneuRx and Excluder endograft systems were offset by the more frequent
need for proximal and distal extensions. The minimum device cost of a basic repair should not factor into the decision to
select one specific device over another because additional devices may be required depending on the design and
construction of the endograft system and the accuracy and reliability of their deployment mechanisms. ( J Vasc Surg
2008;47:499-503.)The repair of infrarenal abdominal aortic aneurysms
(AAA) has undergone a dramatic change during the past
two decades. The traditional open surgical approach has
been largely replaced by endovascular techniques; however,
certain anatomic criteria must still be met to achieve a
successful and durable repair. The cost of these devices has
been a subject of considerable controversy regarding the
overall cost-effectiveness of the therapy and remains a fiscal
obstacle to its wider adoption in certain health care systems.
The current study compared the overall costs of three
of the four currently commercially available devices in the
United States: the AneuRx (Medtronic, Santa Rosa, Calif),
the Excluder (W. L. Gore & Associates, Flagstaff, Ariz),
and the Zenith (Cook, Bloomington, Ind). Specifically, we
sought to compare the costs of completing an endovascular
repair under actual, real-world conditions with an uns-
elected cohort of AAA anatomies that were deemed suit-
able for endovascular therapy.
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We retrospectively reviewed a prospectively maintained
clinical database of all endovascular repairs of AAA (EVAR)
during a 7-year period (2000-2006). All of the procedures
were performed at a single tertiary-care university medical
center by one of five vascular surgeons. Preoperative plan-
ning was based on thin-cut (2- to 3-mm slice thickness)
computed tomography (CT) angiograms with three-
dimensional (3D) reconstructions and center-path analy-
ses performed using one of three software platforms: Med-
ical Metrix Systems (Hanover, NH), Vitrea (Vital Images,
Minnetonka, Minn), and Aquarius (TeraRecon, San Ma-
teo, Calif).
The specific device chosen was determined by its com-
mercial availability at the time of repair (AneuRx, Septem-
ber 1999; Excluder, November 2002; Zenith, May 2003),
patient anatomy, and surgeon preference. The principles of
endovascular repair remained relatively constant through-
out the course of the study regardless of the device used and
were similar amongst the different operating surgeons.
More specifically:
● The main device was routinely deployed as close to the
lowermost renal artery as possible using the full length
of the infrarenal neck. A proximal cuff was used if the
primary device was deployed 10 mm below renal
arteries or if there was 10-mm fixation on comple-
tion angiography, regardless of an endoleak. We be-
lieved that this yielded the best chances for long-term
outcome.
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hypogastric arteries as possible, regardless of common
iliac length. In cases of ectasia (common iliac diameters
20 mm), flared limbs or “bell-bottom” techniques
with aortic cuffs were used.1
During the latter half of the study period, the Excluder
flared contralateral limbs became available (October 2003),
whereas flared limbs were available on both ipsilateral and
contralateral limbs in the Zenith device since its initial
commercial introduction. More recently, Medtronic had
introduced the AneuRx AAAdvantage line extension that
included flared iliac limbs, but the AneuRx implants in-
cluded in this study all occurred before this. In cases where
the iliac artery was 20 mm in diameter without a suitable
landing zone proximal or distal to the aneurysmal segment,
the iliac limb was extended to the external iliac artery with
either surgical revascularization or coil embolization of the
hypogastric artery.
Device configurations and list prices (US $)
Medtronic AneuRx. The minimum construction for
repair using this system is two pieces consisting of a main
body-ipsilateral limb with a covered length of 13.5 and
16.5 cm, and a contralateral limb with a length of 8.5 and
11.5 cm. Straight limb extensions and aortic cuffs ($2025)
were available. At the time of this study, the minimum list
price of one main body ($7250-$7550) and one contralat-
eral limb ($2225-$2425) was $9475. The total cost of the
entire product matrix (30 pieces comprising one of each
diameter and length) was $117,500.
W. L. Gore Excluder. Similar to the AneuRx, this is a
two-piece construction consisting of a main body-ipsilateral
limb ($6980) and a contralateral limb ($3223). The limb
and proximal extenders cost $2259. A simple two-piece
repair would cost $10,203. The cost of the entire inventory
of 39 pieces would be $187,539. This does not reflect the
flared iliac limbs introduced after the original commercial
release of the system.
Cook Zenith. This is a 3-piece system consisting of a
Table I. Demographics and selected procedural measures
Demographic AneuRx
No. of patients 178
Age, mean  SD years 71.7  13.
Female, No. (%) 13 (7.3)
General anesthesia, No. (%) 166 (93.3)
Fluoroscopy, mean  SD min 27.1  11.
IV contrast, mean  SD mL 88.6  30.
Procedure time, mean  SD min 194  75
EBL, mean  SD mL 285  369
Urgency, No. (%)
Elective 159 (89.3)
Symptomatic 11 (6.2)
Ruptured 8 (4.5)
LOS, median (range) days 2 (1–61
EBL, Estimated blood loss; IV, intravenous; LOS, length of stay.main body ($7400) and two iliac limbs ($2700 each). Theminimum cost of a repair was $12,800. Owing to the sheer
number of different diameters and lengths of the main body
and iliac limbs and extensions ($1500), the entire product
matrix consisted of 94 devices at a total cost of $367,300.
This does not reflect the recent introduction of the 36-mm
main body.
Only the direct costs of the devices were analyzed. The
cost of ancillary devices, such as balloons, bare-metal pe-
ripheral stents, and coils, were estimated to be equivalent
among the three devices. Data are presented as mean 
standard deviation where appropriate. The Student t test
for continuous and the Fisher exact test for categoric vari-
ables were used for analysis. Statistical significance was
achieved at P  .05.
RESULTS
During the 7-year period, 467 patients underwent
EVAR using one of the three devices. These included 178
AneuRx (38.1%), 123 Excluder (26.3%), and 166 Zenith
(35.5%) cases. The mean age of patients undergoing EVAR
was 70.5  15.9 years, and 48 (10.3%) were women.
Patient age among the three groups was similar, and each
group had approximately the same proportion of women
(Table I).
Significantly more AneuRx patients underwent general
anesthesia vs local or regional, which was simply reflective
of the anesthetic technique used during that segment of the
study period. The mean estimated blood loss, fluoroscopy
time, and amount of contrast used were similar among the
three groups. The total procedure time was significantly
longer for the AneuRx cohort (194 75 minutes) than for
patients who received the Excluder (135  58 minutes)
and Zenith (133  47 minutes P  .0001). The median
length of stay was 2 days for the AneuRx group, and 1 day
for the Excluder and Zenith groups (Table I).
The proportion of patients requiring elective EVAR
was similar among the three devices. In the entire cohort,
450 patients (96.4%) had an intact aneurysm at the time of
repair. The mean maximal aortic diameters (60.0  12.5
ng the three devices studieda
Excluder Zenith
123 166
68.9  18.6 71.1  14.4
14 (11.4) 21 (12.7)
61 (49.6) 74 (44.6)
21.1  12.7 28.1  11.5
92.5  43.1 103.6  44.2
135  58 133  47
235  291 227  125
110 (89.4) 159 (95.6)
5 (4.1) 6 (3.6)
8 (6.5) 1 (0.6)
1 (1–40) 1 (0–26)amo
5
1
5
)mm for AneuRx, 57.5 9.5 mm for Excluder, and 59.8
s (P 
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lengths were comparable in all groups (Table II). Slightly
fewer patients in the Excluder group had a concomitant
iliac aneurysm compared with the rest of the cohort (23.5%
for Excluder vs 33.7% for AneuRx and Zenith, P  .05).
Each AneuRx repair required an average of 1.90 exten-
sions (range, 0-7). By comparison, the Excluder device
required 1.19 extensions per case (range, 0-4), and the
Zenith required 0.21 extensions per case (range, 0-3;
Table III, Fig 1). When the cost of the extensions was
included, the differences in the overall costs of the en-
dografts for the three types of repairs were small and$500
of each other.
Of interest was that although the basic cost of the
AneuRx two-piece repair was the least expensive, in actual
practice it was the most costly, and the Zenith system,
Table II. Abdominal aortic aneurysm anatomy among the
Anatomy AneuR
Intact, No (%) 170 (95.
AAA size, mean  SD mm 60.0  1
Neck diameter, mean  SD mm 22.8  2
Neck length, mean  SD mm 29.3  1
Iliac aneurysm, No (%) 63 (35.
aPatients who had an Excluder repair had fewer concomitant iliac aneurysm
Table III. Extension usage among the three devices
Extensions Aneu
Total extensions, No. 33
Proximal 10
Distal 23
Extensions per case
Cost of extension $202
Cost of extensions per case, mean $385
2- or 3-piece repair, minimum cost $9,47
Total mean costa $13,33
Cost relative to AneuRx $
a2-or 3-piece construction  cost of extension.
Fig 1. Histogram of extension usage for each device. Most of the
AneuRx cases required two or more extensions to complete the
repair, and 68.3% of Excluder cases required at least one extension
to complete the repair. For the Zenith implants, 83.1% of patients
required only the basic three-piece configuration, without any
additional pieces.whose basic three-piece construction was the most expen-sive, actually cost less than the AneuRx (Fig 2). The Ex-
cluder and Zenith endografts required obligatory balloon-
ing with a compliant aortic occlusion balloon to mold the
endograft attachment sites and junctions, whereas the
AneuRx did not. Factoring the approximate $350 cost of
this balloon, however, did not materially alter the overall
mean device cost of the repairs.
To determine if the number of extensions used was
reflective of a device-specific learning curve, we compared
the mean number of extensions used for each of the three
devices in the first 30 patients and compared that with
the last 30 patients with the same device. Surgeon experi-
ence appeared to show an inconsistent effect on extension
usage (Table IV). The number of extensions used with the
AneuRx device increased significantly, whereas the number
of extensions required among patients repaired with a
Zenith device decreased with experience. Some of this may
represent the paradox of learning curve, where more com-
plex cases are treated as experience is gained, which in turn
e devices
Excluder Zenith
115 (93.5) 165 (99.4)
57.5  9.5 59.8  10.8
22.2  2.3 25.2  3.2
33.9  13.9 31.1  14.0
29 (23.6)a 53 (31.9)
.05).
Excluder Zenith
146 35
47 0
99 35
1.19 0.21
$2259 $1500
$2681 $316
$10,203 $12,800
$12,884 $13,116
$448 $216
Fig 2. Mean overall cost of the endograft (cost of the basic 2- or
3-piece construction plus the mean cost of extensions) per case.thre
x
5)
2.5
.1
6.8
6)Rx
9
5
4
1.90
5
7
5
2
0may require a higher number of devices.
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AneuRx (16.3%), 13 Excluder (10.6%), and six Zenith
(3.6%) patients. For those late secondary procedures that
required placement of extensions, more proximal exten-
sions were used for the AneuRx device (n  13) than
Excluder (n  0) and Zenith (n  1) devices. Similarly,
distal extensions were required more frequently with
AneuRx (n  6) than Excluder (n  3) or Zenith (n  0).
It should be noted, however, that reintervention is a time-
dependent event, and the AneuRx cohort had the longest
mean follow-up among the three groups.
DISCUSSION
This study examined the real-life costs of different
endograft systems used to treat an unselected, consecutive
series of patients with AAA suitable for EVAR. Our results
showed that the basic cost of repair—meaning the mini-
mum number of devices required to achieve a bifurcated
construction— does not tell the whole story. Indeed, de-
spite an initial cost differential of $3000 from the least
expensive device to the most expensive device, in the final
analysis, the mean cost of actual repair differed by $500
among the three devices.
The reasons for this include what is considered “opti-
mal” endovascular repair, endograft-dependent factors,
and the current limitations of sizing and planning. In our
practice, we strongly believed that optimal repair is
achieved with maximal coverage of the proximal and distal
landing zones. Although there is little controversy about
deployment of themain body as close to the renal arteries as
possible,2 there is some controversy about the routine
extension of the iliac limbs to the hypogastric arteries,3,4
especially when there is 2 cm or more of relatively undis-
eased or nonaneurysmal artery. As reported by Arko et al,5
for the AneuRx system, which relies on columnar support
as an important mechanism of fixation, it has been shown
that full coverage of the common iliac arteries resulted in
better late outcomes in terms of migration and limb retrac-
tion. Furthermore, there is a small but definite risk of late
aneurysmal degeneration of the uncovered iliac segment.
Once commercialization of a medical device occurs,
application of that device in anatomic situations outside of
the manufacturer’s instructions for use (IFU) is common.
This is obviously in contrast to the strict constraints of
clinical trials that comprise the initial experience of any new
medical technology. In the idealized conditions of a clinical
Table IV. Rate of extension usage (mean  SD)
between the first and last 30 consecutive series of patients
for each device
Group AneuRx Excluder Zenith
First 30 cases 1.53  1.22 0.83  0.95 0.47  0.68
Last 30 cases 2.40  1.19 1.30  1.18 0.13  0.57
P .007 .09 .04trial and strict guidelines of the device IFU, our results maynot hold. However, when such restrictions are lifted by
operator discretion, off-label use of additional devices, such
as aortic cuffs in iliac limbs, occurs frequently. It is in this
context that the results of this study should be viewed.
In this study, 3D reconstructions of CT angiograms
were used routinely for preoperative planning and sizing of
the cases. Conventional preoperative angiography with
marker catheters was rarely used. Although diameter mea-
surements have become fairly reliable, path-length mea-
surements remain the least reliable indicator in endograft
sizing and planning, regardless of which method is used.
Axial CT tends to underestimate the path length, 3D
reconstructions tend to overestimate, and angiography falls
somewhere in between, depending on a host of anatomic
factors and techniques. In practice, “fudge-factors” are
used to compensate for these variabilities in the different
imaging modalities. One of the main indications for addi-
tional extensions in the AneuRx and Excluder cases in this
series was to achieve limb extensions to the hypogastric
arteries when a shorter main body and contralateral limb
was purposely selected in borderline cases to avoid inadver-
tent coverage of the hypogastric artery.
Arguably, had an accurate and reliable method of
length measurement been available, iliac extension usage
could have been decreased. Alternatively, a method of
“trombone-ing” the iliac limb within the docking gate of
the main body would allow sufficient intraoperative flexi-
bility to overcome this preplanning deficiency. This con-
cept of intraoperative adjustability of the iliac limbs can be
extended not only to just the contralateral limb but also to
both limbs to provide the maximum degree of deployment
flexibility.
Another method of potentially reducing extension us-
age would be, theoretically, to stock an unlimited inventory
where intraoperative selection of any device can be made
on-the-fly. Even with wider availability of consignment
stock by the different manufacturers, it is generally imprac-
tical from the standpoint of space and inventory manage-
ment to stock the entire product matrix. A more realistic
alternative is if multiple lengths of the same diameter de-
vices could be ordered without additional financial burden
(per-case consignment) so that the operator has the option
of choosing the optimal lengths of the devices at the time of
the procedure and pay for only those devices used for
repair. During the period of this study, such purchase
agreements were not available, and ordering two main
bodies of differing lengths was not a fiscally viable practice.
On the other hand, the capacity to have some method of
adjusting length built into the device would help in the
amount of inventory one would have to stock. Along these
lines, a larger variety of device configurations would further
obviate the need for aortic cuff usage for “bell-bottoming”
purposes. Although not applicable for this study, flared iliac
limbs are now available for all the devices examined in this
article.
Deployment accuracy also affects cuff and extension
usage. Especially proximally, in cases of neck angulation,
different mechanisms of deployment can significantly influ-
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suboptimal deployment. Indeed for AneuRx and Excluder
cases, proximal cuffs accounted for 31% and 32%, res-
pectively, of the entire extension usage (vs 0% for Zenith;
Table III).
The study has a number of limitations. First, as men-
tioned, the more recent expansions to the product lines of
the respective devices were not considered. Most of the
experience reported here predated the additional sizes and
lengths that could have materially impacted the overall
results and their applicability.
Second, although only the endograft costs were con-
sidered, there may be other ancillary disposable equipment
unique to a particular endograft system that could impact
the overall device-related cost of the procedures. However,
any variability would likely have been a small fraction of the
overall cost.
In a related manner, this analysis was based on a static
cost of the devices. Were those prices to change signifi-
cantly, our results might be significantly altered. To our
knowledge, although the AneuRx device has been dis-
counted slightly from its original list price, no substantial
price changes have occurred in any of the other endograft
systems. Given the current competitive marketplace, how-
ever, creative consignment and purchasing programs indi-
vidually negotiated between the hospital and the vendor are
more widely available today than in the early years of this
study. This could affect the ability to intraoperatively
change device selections and lower the need for extensions.
Third, our bias of routine iliac extension to the hypo-
gastric arteries is not supported by any clear scientific
evidence of improved patient outcome. If such a policy had
not been practiced, the results could have been significantly
different than reported.
Fourth, complexity of an endograft system (2-piece vs
3-piece construction, single-stage deployment vs multi-
stage deployment) may lead to prolongation of procedure
time and increased operating room costs. Of interest, how-
ever, was that the mean procedure time was almost 60
minutes longer for the AneuRx procedures than for the
Excluder and Zenith procedures. This may be a reflection
of a learning curve effect and the additional time expended
for implantation of the extensions.
Finally, we did not consider the Powerlink (Endologix,
Irvine, Calif) device, a unibody device that may offer a
significant competitive fiscal advantage compared with the
other three devices.
In this study, we arbitrarily chose a rather narrow
measure of “device cost” as a measure of the cost of repairamong many other equivalent or potentially even more
valid surrogate measures. Arguably, in endovascular repair,
the cost of the endograft comprises a dominant component
of the immediate cost of the therapy because other factors
such as use ancillary devices, routine postoperative care, and
lengths of stay are all fairly similar. As far as the overall cost
of EVAR is concerned, clearly, many other factors must be
considered such as follow-up imaging and the cost of
reinterventions, which speaks more to the long-term effi-
cacy of a particular device.
CONCLUSION
The basic cost of repair using a particular device does
not always equal the actual cost. In fact, the overall costs of
the devices were fairly equivalent among the three devices
considered. Therefore, the minimum cost of the two- or
three-piece construction should not influence the decision
to use a particular endograft system from a fiscal standpoint.
A large product matrix and ability for intraoperative adjust-
ment of lengths may reduce need for additional devices and
the final endograft-related cost of repair.
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